John Taper

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Harry Iland, Ken Bradstock, Shane G. Supple et al. · Blood · 2012 · 336 citations · Full text

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Harry Iland, Marnie Collins, Ken Bradstock et al. · The Lancet Haematology · 2015 · 165 citations

Hematological Malignancy, Oncology, Malignant Blood Disorder +8

A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study

James S. Wiley, Lan‐Phuong Dao‐Ung, Ben J. Gu et al. · The Lancet · 2002 · 165 citations

Somatic Variant, Chronic Lymphocytic Leukaemia, Medicine +9

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

David T Yeung, Michael Osborn, Deborah L. White et al. · Blood · 2014 · 102 citations · Full text

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Mark Hertzberg, Maher K. Gandhi, Judith Trotman et al. · Haematologica · 2016 · 55 citations · Full text